Jo Caers

12.0k total citations · 2 hit papers
95 papers, 2.4k citations indexed

About

Jo Caers is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Jo Caers has authored 95 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 64 papers in Hematology, 40 papers in Molecular Biology and 37 papers in Oncology. Recurrent topics in Jo Caers's work include Multiple Myeloma Research and Treatments (57 papers), Protein Degradation and Inhibitors (14 papers) and Peptidase Inhibition and Analysis (10 papers). Jo Caers is often cited by papers focused on Multiple Myeloma Research and Treatments (57 papers), Protein Degradation and Inhibitors (14 papers) and Peptidase Inhibition and Analysis (10 papers). Jo Caers collaborates with scholars based in Belgium, France and Austria. Jo Caers's co-authors include Roy Heusschen, Victor L. Thijssen, Arjan W. Griffioen, Yves Béguin, Karin Vanderkerken, Heinz Ludwig, Hendrik De Raeve, Eline Menu, Joséphine Muller and Benjamin Van Camp and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Jo Caers

86 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma

2022 350 citations Niels W.C.J. van de Donk, Jo Caers et al. profile →
Extramedullary disease in multiple myeloma: a systematic literature review

2022 111 citations Jo Caers et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jo Caers Belgium	23	1.1k	1.1k	934	557	223	95	2.4k
Ralph Wäsch Germany	31	1.6k 1.4×	2.1k 1.9×	1.2k 1.3×	389 0.7×	129 0.6×	172	3.3k
Edward N. Libby United States	22	1.1k 1.0×	1.2k 1.1×	1.1k 1.2×	224 0.4×	246 1.1×	87	2.5k
Ollivier Legrand France	31	1.3k 1.1×	1.5k 1.3×	1.5k 1.7×	249 0.4×	175 0.8×	93	3.2k
Peter Gimsing Denmark	31	1.9k 1.7×	2.1k 1.9×	1.4k 1.5×	324 0.6×	153 0.7×	111	3.1k
Michael Medinger Switzerland	27	927 0.8×	727 0.7×	739 0.8×	269 0.5×	143 0.6×	106	2.3k
H M Lokhorst Netherlands	35	1.7k 1.5×	2.3k 2.0×	1.5k 1.6×	583 1.0×	250 1.1×	80	3.6k
Christof Scheid Germany	28	578 0.5×	1.1k 1.0×	648 0.7×	472 0.8×	136 0.6×	149	2.2k
Hyeoung‐Joon Kim South Korea	29	1.0k 0.9×	1.4k 1.2×	909 1.0×	957 1.7×	111 0.5×	213	3.0k
Ulf‐Henrik Mellqvist Sweden	24	739 0.7×	1.4k 1.3×	664 0.7×	486 0.9×	73 0.3×	60	2.2k
Tibor Kovacsovics United States	29	1.4k 1.2×	2.3k 2.1×	880 0.9×	433 0.8×	123 0.6×	123	3.7k

Countries citing papers authored by Jo Caers

Since Specialization

Citations

This map shows the geographic impact of Jo Caers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jo Caers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jo Caers more than expected).

Fields of papers citing papers by Jo Caers

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jo Caers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jo Caers. The network helps show where Jo Caers may publish in the future.

Co-authorship network of co-authors of Jo Caers

This figure shows the co-authorship network connecting the top 25 collaborators of Jo Caers. A scholar is included among the top collaborators of Jo Caers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jo Caers. Jo Caers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ho, Patrick, Céline Grégoire, AnneMarie W. Block, et al.. (2025). Fine tuning towards the next generation of engineered T cells. Nature Biomedical Engineering. 9(10). 1610–1631.

Grégoire, Céline, et al.. (2024). Chimeric antigen receptor T‐cell therapy for haematological malignancies: Insights from fundamental and translational research to bedside practice. British Journal of Haematology. 205(5). 1699–1713. 5 indexed citations

Donk, Niels W.C.J. van de, et al.. (2023). Rationale for and Design of Papilio-1: A Phase 1/2, Multicenter, Open-Label Study to Evaluate the Feasibility, Safety, and Efficacy of Point-of-Care-Manufactured Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells (GLPG5301) in Relapsed/Refractory Multiple Myeloma. Blood. 142(Supplement 1). 4859–4859. 1 indexed citations

Terpos, Evangelos, Renato Zambello, Xavier Leleu, et al.. (2022). Real-World Use and Effectiveness of Carfilzomib Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma in Europe. Cancers. 14(21). 5311–5311. 5 indexed citations

Leleu, Xavier, Eirini Katodritou, Evangelos Terpos, et al.. (2022). Real‐world use of carfilzomib combined with lenalidomide and dexamethasone in patients with multiple myeloma in Europe and Israel. SHILAP Revista de lepidopterología. 4(1). 174–183. 5 indexed citations

Caers, Jo, Guillaume Marcion, Kim De Veirman, et al.. (2022). Radiotheranostic Agents in Hematological Malignancies. Frontiers in Immunology. 13. 911080–911080. 8 indexed citations

Gamper, Eva‐Maria, Francesco Cottone, Kathrin Sommer, et al.. (2021). The EORTC QLU-C10D was more efficient in detecting clinical known group differences in myelodysplastic syndromes than the EQ-5D-3L. Journal of Clinical Epidemiology. 137. 31–44. 20 indexed citations

Dubois, Sophie, Laurence Seidel, Jo Caers, et al.. (2021). Itacitinib prevents xenogeneic GVHD in humanized mice. Bone Marrow Transplantation. 56(11). 2672–2681. 20 indexed citations

Bolomsky, Arnold, Meike Vogler, Caroline A. Heckman, et al.. (2020). MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents. Journal of Hematology & Oncology. 13(1). 173–173. 117 indexed citations

10.

Einsele, Hermann, et al.. (2020). Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies. Frontiers in Immunology. 11. 762–762. 59 indexed citations

11.

Gavriatopoulou, Maria, Pellegrino Musto, Jo Caers, et al.. (2018). European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. Leukemia. 32(9). 1883–1898. 60 indexed citations

12.

Heusschen, Roy, Joséphine Muller, Nadia Withofs, et al.. (2017). Multiple myeloma bone disease: from mechanisms to next generation therapy. Open Repository and Bibliography (University of Liège). 1 indexed citations

13.

Bolomsky, Arnold, Roy Heusschen, Joséphine Muller, et al.. (2017). Preclinical Evaluation of the First in Class BMI1 Inhibitor PTC-028 Confirms Potent Efficacy to Target BMI1-Addiction in Multiple Myeloma. Blood. 130. 1804–1804. 1 indexed citations

14.

Bolomsky, Arnold, Roy Heusschen, Karin Schlangen, et al.. (2017). Maternal embryonic leucine zipper kinase is a novel target for proliferation-associated high-risk myeloma. Haematologica. 103(2). 325–335. 24 indexed citations

15.

Hannon, Muriel, Stéphanie Humblet‐Baron, Étienne Baudoux, et al.. (2015). Impact of the immunomodulating peptide thymosin alpha 1 on multiple myeloma and immune recovery after hematopoietic stem cell transplantation. Cancer Immunology Immunotherapy. 64(8). 989–998. 4 indexed citations

16.

Malaise, Olivier, Sophie Servais, Daniela Betea, et al.. (2012). Panhypopituitarism and diabetus insipidus in a patient with primary central nervous system lymphoma. Open Repository and Bibliography (University of Liège).

17.

Bonnet, Christophe, et al.. (2011). [b]Lymphome[/b] du manteau : prise en charge 2011. Revue Médicale Suisse. 7(306). 1644–1649. 1 indexed citations

18.

Théate, Ivan, et al.. (2009). Diffuse xanthomatosis as a presenting feature of multiple myeloma. European Journal Of Haematology. 84(5). 460–461. 2 indexed citations

19.

Bruyne, Elke De, Thomas Levin Andersen, Hendrik De Raeve, et al.. (2006). Endothelial cell-driven regulation of CD9 or motility-related protein-1 expression in multiple myeloma cells within the murine 5T33MM model and myeloma patients. Leukemia. 20(10). 1870–1879. 19 indexed citations

20.

Caers, Jo, Kewal Asosingh, Ben Van Camp, Ivan Van Riet, & Karin Vanderkerken. (2004). Of mice and men, disease models of multiple myeloma.. Open Repository and Bibliography (University of Liège). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact